Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts. Show more

209 CHURCH STREET, NEW HAVEN, CT, UNITED STATES, 06510, New Haven, CT, 06510, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

202M

52 Wk Range

$0.48 - $3.07

Previous Close

$0.73

Open

$0.70

Volume

1,978,310

Day Range

$0.68 - $0.72

Enterprise Value

27.02M

Cash

184.2M

Avg Qtr Burn

-41.71M

Insider Ownership

7.07%

Institutional Own.

89.27%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PEMGARDA (Pemivibart) (VYD222) Details COVID-19	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VYD2311 Details COVID-19	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Adintrevimab (ADG20) Details COVID-19	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VYD2311 (Monoclonal Antibody) Details Long COVID / COVID Vaccine Injury	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.